Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - Guggenheim has raised its price target on Abbvie (NYSE:ABBV) to $242.00 from $227.00 while maintaining a Buy rating ahead of the company’s third-quarter earnings release scheduled for October 31. The pharmaceutical giant, currently trading at $229.57 with a market capitalization of $405.5 billion, has shown strong momentum according to InvestingPro data.
The price target increase is primarily driven by Guggenheim’s revised timeline for Rinvoq’s expected U.S. loss of exclusivity, which has been extended by approximately four years to April 2037 following legal settlements with various generic manufacturers.
Abbvie stock has performed strongly in 2025, gaining approximately 27.5% year-to-date, significantly outpacing the S&P 500’s 13.7% increase during the same period.
Guggenheim notes that investors continue to view Abbvie as an attractive investment opportunity due to the company’s solid visibility on both top-line and bottom-line growth outlook through the end of the decade.
The firm’s updated price target is derived from a discounted cash flow analysis that incorporates the extended market exclusivity period for Rinvoq, one of Abbvie’s key immunology products.
In other recent news, AbbVie announced significant results from its Phase 3b/4 SELECT-SWITCH trial. The study demonstrated that its JAK inhibitor, upadacitinib, outperformed adalimumab in treating moderate to severe rheumatoid arthritis, showing higher rates of low disease activity and remission at 12 weeks. AbbVie also completed the acquisition of bretisilocin, a novel psychedelic compound from Gilgamesh Pharmaceuticals, currently in Phase 2 clinical development for major depressive disorder. In analyst updates, Raymond James raised its price target for AbbVie to $250, maintaining an Outperform rating, attributing this to strong prescription trends and the company’s performance in the third quarter. Cantor Fitzgerald reiterated its Overweight rating on AbbVie, setting a price target of $250 and adjusting its earnings model due to tax impacts from an IPR&D charge. Conversely, Erste Group downgraded AbbVie from Buy to Hold, citing the company’s recent reduction in its full-year 2025 adjusted earnings per share guidance. These developments reflect a dynamic period for AbbVie, with varied analyst perspectives and strategic acquisitions shaping its outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.